Cassetta Luca, Pollard Jeffrey W
MRC Centre for Reproductive Health, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK.
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, New York 10461, USA.
Cell Res. 2017 Aug;27(8):963-964. doi: 10.1038/cr.2017.63. Epub 2017 Apr 21.
Tumor-associated macrophages (TAMs) contribute to breast cancer progression and dissemination; TAM-targeting strategies aimed at their reprogramming show promising preclinical results. In a new report Guerriero and colleagues demonstrate that a novel HDAC Class IIa inhibitor, TMP195, can reprogram monocytes and macrophages in the tumor into cells able to sustain a robust CD8 T cell-mediated anti-tumoral immune response.
肿瘤相关巨噬细胞（TAMs）促进乳腺癌的进展和扩散；旨在对其进行重编程的TAM靶向策略在临床前研究中显示出有前景的结果。在一项新报告中，Guerriero及其同事证明，一种新型的IIa类组蛋白去乙酰化酶（HDAC）抑制剂TMP195能够将肿瘤中的单核细胞和巨噬细胞重编程为能够维持强大的CD8 T细胞介导的抗肿瘤免疫反应的细胞。
